National Comprehensive Cancer Network, Abraxis BioScience, Inc. And AstraZeneca LP Announce Collaboration To Conduct Anti-Cancer Drug Studies

FORT WASHINGTON, Pa.--(BUSINESS WIRE)--The National Comprehensive Cancer Network (NCCN), Abraxis BioScience (NASDAQ:ABII), and AstraZeneca (NYSE:AZN) today announced that they have entered into a collaboration to conduct multiple investigator-initiated studies of Abraxis BioScience’s anti-cancer drug ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound), which is based on the company’s proprietary tumor targeting technology known as the nab™ platform.

Back to news